Highland Marketing, a full service agency for health techmarketing, PR and communications, has appointed Tia Dissanayake to a new account executive role,in which she will support the team withher life science knowledge.
Tia has a strong background in science, having studied biology at university andworked withinthe healthcare and medical sectors.
Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The new lab aims to bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide. 
Patient Safety Learning today announced acampaign to end the thousands of avoidable deaths each year from unsafe patient care. The charity is calling for a new approach throughout all areas of the health and social care system to ensure improvements in patient safety. This involves providers, commissioners, policy makers, regulators, patient groups, and individual patients and families. 
Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, announced that it has signed a new agreement with IBM Watson Health to co-develop and co-commercialize an artificial intelligence (AI) solution to help clinicians diagnose and monitor patients with prostate cancer. 
Professionals from across the country will come together to seek real answers on how to deliver closely integrated services, as the Joined Up Health and Care conference returns for its sixth year on 10th October at The Vox in Birmingham. 
Health technology specialist IMS MAXIMS has been recognised for its innovative work in the UK and Irish healthcare market in the 2019 CV Business Innovator Awards. The company has been named as the leading innovator in healthcare administration software, in recognition of the quality of its patient administration system and electronic patient record solutions, which it provides to more than 180 healthcare organisations. 
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the commercial launch of Philips NightBalance, a prescription sleep position therapy device designed for patients with positional obstructive sleep apnea (OSA).